Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature.

J Cancer Res Ther

Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China.

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is becoming a promising option for multiple tumor types, including triple-negative breast cancer. This report presents a case of triple-negative MpBC that achieved a complete response with a combination of chemotherapy and immune checkpoint inhibitors. We examined the tumor's imaging and histological features, along with the treatment regimen and efficacy. Notably, no major toxicities related to immunotherapy were observed. To our knowledge, this is the first case report demonstrating the effectiveness of lambrolizumab in combination with the GP chemotherapy regimen for treating triple-negative breast cancer in general and specifically metastatic MpBC.

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.jcrt_285_25DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
complete response
8
metaplastic breast
8
immune checkpoint
8
case report
8
triple-negative breast
8
combination chemotherapy
8
breast
5
cancer
5
response patient
4

Similar Publications

Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.

View Article and Find Full Text PDF

Background: Iron metabolism may influence breast cancer development; however, links between iron-related biomarkers and breast cancer remain inconclusive. Given differences in iron status by menopausal status, we examined associations of ferritin and other iron biomarkers, with breast cancer incidence, stratified by menopausal status, in a Korean screening cohort.

Methods: This cohort study included 140,747 Korean women screened for breast cancer from 2011-2020.

View Article and Find Full Text PDF

Background: Alcohol consumption is a risk factor for certain cancers and is increasing in the United States. We estimated the impact of alcohol consumption on cancer incidence trends in the United States from 2008-2019 across six alcohol-related cancers among men and women.

Methods: Average daily alcohol consumption (ADC) was calculated from the National Health Interview Survey (NHIS, 1998-2009) and adjusted to per capita sales data to account for underreporting alcohol use.

View Article and Find Full Text PDF

Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF